Dawson James analyst James McIlree upgrades Arcimoto (NASDAQ:FUV) from Sell to Neutral.
Investors’ Focus Around Amgen’s Obesity Drug Data Shadows Better Than Expected Q4 Earnings
Amgen's Q4 2023: 15% net profit growth, $8.2 billion total revenues beat expectations. Prolia leads with 12% sales jump. Analysts' reactions and price targets.